Substituted pyridazines as EGFR and/or KRAS inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9562019
APP PUB NO 20130131062A1
SERIAL NO

12520256

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHNEW YORK NY 10021

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chucholowski, Alexander San Diego, US 33 351
Djaballah, Hakim Scarsdale, US 20 131
Shum, David Forest Hills, US 3 40
Somwar, Romel New York, US 2 27
Thiruvazhi, Mohan Santhanam San Diego, US 4 70
Varmus, Harold E New York, US 2 27

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 7, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00